Takeshi Hirose

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Venues

NPJ precision oncology

Cancer science

Journal of personalized medicine

Oncogene

This page only lists publications with an associated author ORCID identifier.

Publications

Kengo Kawaguchi, Kazuki Miyama, Makoto Endo, Ryoma Bise, Kenichi Kohashi, Takeshi Hirose, Akira Nabeshima, Toshifumi Fujiwara, Yoshihiro Matsumoto, Yoshinao Oda, Yasuharu Nakashima
Viable tumor cell density after neoadjuvant chemotherapy assessed using deep learning model reflects the prognosis of osteosarcoma. NPJ precision oncology 8 (1) (2024)
Kengo Kawaguchi, Kazuki Miyama, Makoto Endo, Ryoma Bise, Kenichi Kohashi, Takeshi Hirose, Akira Nabeshima, Toshifumi Fujiwara, Yoshihiro Matsumoto, Yoshinao Oda, Yasuharu Nakashima
Viable tumor cell density after neoadjuvant chemotherapy assessed using deep learning model reflects the prognosis of osteosarcoma. NPJ precision oncology 8 (1) (2024)
Kengo Kawaguchi, Kazuki Miyama, Makoto Endo, Ryoma Bise, Kenichi Kohashi, Takeshi Hirose, Akira Nabeshima, Toshifumi Fujiwara, Yoshihiro Matsumoto, Yoshinao Oda, Yasuharu Nakashima
Viable tumor cell density after neoadjuvant chemotherapy assessed using deep learning model reflects the prognosis of osteosarcoma. NPJ precision oncology 8 (1) (2024)
Takeshi Hirose, Masachika Ikegami, Shinya Kojima, Akihiko Yoshida, Makoto Endo, Eijiro Shimada, Masaya Kanahori, Ryunosuke Oyama, Yoshihiro Matsumoto, Yasuharu Nakashima, Akira Kawai, Hiroyuki Mano, Shinji Kohsaka
Extensive analysis of 59 sarcoma-related fusion genes identified pazopanib as a potential inhibitor to COL1A1-PDGFB fusion gene. Cancer science (2023)
Hiroshi Ikeuchi, Takeshi Hirose, Masachika Ikegami, Kazuya Takamochi, Kenji Suzuki, Hiroyuki Mano, Shinji Kohsaka
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model. Oncogene 41 (17) (2022)
Eijiro Shimada, Makoto Endo, Yoshihiro Matsumoto, Kenji Tsuchihashi, Mamoru Ito, Hitoshi Kusaba, Akira Nabeshima, Tomoya Nawata, Akira Maekawa, Tomoya Matsunobu, Nokitaka Setsu, Toshifumi Fujiwara, Keiichiro Iida, Makoto Nakagawa, Takeshi Hirose, Masaya Kanahori, Ryunosuke Oyama, Taichi Isobe, Hiroshi Ariyama, Kenichi Kohashi, Hidetaka Yamamoto, Yoshinao Oda, Yukihide Iwamoto, Koichi Akashi, Eishi Baba, Yasuharu Nakashima
Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients? Journal of clinical medicine 10 (21) (2021)
Tom Wei-Wu Chen, Angela Pang, Mark E Puhaindran, Myo Myint Maw, Herbert H Loong, Virote Sriuranpong, Chih-Chi Chang, Siyamol Mingmalairak, Takeshi Hirose, Makoto Endo, Akira Kawai, Mohamad Farid, Sze Huey Tan, Wei Lin Goh, Richard Quek, Jeffrey C H Chan, Alex K C Leung, Roger K C Ngan
The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium. Cancer science 112 (3) (2021)
Ryuto Tsuchiya, Yuki Yoshimatsu, Rei Noguchi, Yooksil Sin, Takuya Ono, Taro Akiyama, Takeshi Hirose, Shintaro Iwata, Akihiko Yoshida, Seiji Ohtori, Akira Kawai, Tadashi Kondo
Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma. Journal of personalized medicine 11 (11) (2021)
Masachika Ikegami, Shinji Kohsaka, Takeshi Hirose, Toshihide Ueno, Satoshi Inoue, Naoki Kanomata, Hideko Yamauchi, Taisuke Mori, Shigeki Sekine, Yoshihiro Inamoto, Yasushi Yatabe, Hiroshi Kobayashi, Sakae Tanaka, Hiroyuki Mano
MicroSEC filters sequence errors for formalin-fixed and paraffin-embedded samples. Communications biology 4 (1) (2021)

Takeshi Hirose.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Takeshi Hirose